Compare Neurocrine Biosciences Inc (NBIX) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs US Bancorp — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while US Bancorp trades at $63.14 (market cap $98.36B). The key difference: US Bancorp is far larger — about 5.7× Neurocrine Biosciences Inc's market cap, and US Bancorp pays a 3.29% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | USB | |
|---|---|---|
Market Cap | $17.40B | $98.36B |
Sector | Health | Financials |
52-Week High | $180.55 | $64.01 |
52-Week Low | $123.10 | $43.94 |
Enterprise Value | $16.49B | — |
Dividend Yield | — | 3.29% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
